Acorda Therapeutics Announces Nasdaq Delisting Notification
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Nasdaq Stock Market ("Nasdaq") today notified the Company that it will suspend trading in and delist the Company's common stock, effective with the opening of business on April 12, 2024.
- Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Nasdaq Stock Market ("Nasdaq") today notified the Company that it will suspend trading in and delist the Company's common stock, effective with the opening of business on April 12, 2024.
- The notice follows the Company's April 1, 2024 announcement that it has reached an agreement with Merz Therapeutics to acquire substantially all of the assets of the Company.
- In connection with that announcement, Acorda and certain of its affiliates filed voluntary petitions to commence Chapter 11 proceedings in the U.S. Bankruptcy Court for the Southern District of New York.
- Once the delisting takes effect, Acorda expects its common stock to begin trading on the Pink Open Market (commonly referred to as the “pink sheets”).